The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The FDA has approved Yeztugo, a twice-yearly HIV injection by Gilead shown to virtually eliminate new infections.

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...

The Food and Drug Administration has approved a highly effective new HIV prevention medication, known as Yeztugo. In clinical ...

Gilead has plans for a rapid launch in the United States as well as a wider rollout of the drug in collaboration with global ...

FDA approves Gilead Sciences' groundbreaking HIV prevention injection, Yeztugo, with 99.9% effectiveness, but high cost ...

Learn more about lenacapavir, the most effective HIV treatment and prevention drug, and how its cost could cause a setback.

Gilead Sciences has received US FDA approval for Yeztugo, its bi-annual HIV prevention injection, which has shown 96 per cent ...

Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...